127 related articles for article (PubMed ID: 11428519)
1. Correlation between bradykinin-induced blood-tumor barrier permeability and B2 receptor expression in experimental brain tumors.
Liu Y; Hashizume K; Chen Z; Samoto K; Ningaraj N; Asotra K; Black KL
Neurol Res; 2001 Jun; 23(4):379-87. PubMed ID: 11428519
[TBL] [Abstract][Full Text] [Related]
2. Repeated, short-term ischemia augments bradykinin-mediated opening of the blood-tumor barrier in rats with RG2 glioma.
Liu Y; Hashizume K; Samoto K; Sugita M; Ningaraj N; Asotra K; Black KL
Neurol Res; 2001 Sep; 23(6):631-40. PubMed ID: 11547933
[TBL] [Abstract][Full Text] [Related]
3. Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide.
Nakano S; Matsukado K; Black KL
Cancer Res; 1996 Sep; 56(17):4027-31. PubMed ID: 8752174
[TBL] [Abstract][Full Text] [Related]
4. Intracarotid low dose bradykinin infusion selectively increases tumor permeability through activation of bradykinin B2 receptors in malignant gliomas.
Matsukado K; Sugita M; Black KL
Brain Res; 1998 May; 792(1):10-5. PubMed ID: 9593802
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of bradykinin type 2 receptors on glioma cells enhances bradykinin-mediated blood-brain tumor barrier permeability increase.
Uchida M; Chen Z; Liu Y; Black KL
Neurol Res; 2002 Dec; 24(8):739-46. PubMed ID: 12500695
[TBL] [Abstract][Full Text] [Related]
6. Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors.
Nomura T; Inamura T; Black KL
Brain Res; 1994 Oct; 659(1-2):62-6. PubMed ID: 7529648
[TBL] [Abstract][Full Text] [Related]
7. Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability into brain tumors.
Sugita M; Black KL
Cancer Res; 1998 Mar; 58(5):914-20. PubMed ID: 9500450
[TBL] [Abstract][Full Text] [Related]
8. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors.
Inamura T; Nomura T; Bartus RT; Black KL
J Neurosurg; 1994 Nov; 81(5):752-8. PubMed ID: 7931623
[TBL] [Abstract][Full Text] [Related]
9. Bradykinin selectively opens blood-tumor barrier in experimental brain tumors.
Inamura T; Black KL
J Cereb Blood Flow Metab; 1994 Sep; 14(5):862-70. PubMed ID: 8063881
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide and cyclic GMP attenuate sensitivity of the blood-tumor barrier permeability to bradykinin.
Sugita M; Hunt GE; Liu Y; Black KL
Neurol Res; 1998 Sep; 20(6):559-63. PubMed ID: 9713849
[TBL] [Abstract][Full Text] [Related]
11. Selective tumor blood-brain barrier opening with the kinin B2 receptor agonist [Phe(8)psi(CH(2)NH)Arg(9)]-BK in a F98 glioma rat model: an MRI study.
Côté J; Savard M; Bovenzi V; Dubuc C; Tremblay L; Tsanaclis AM; Fortin D; Lepage M; Gobeil F
Neuropeptides; 2010 Apr; 44(2):177-85. PubMed ID: 20080302
[TBL] [Abstract][Full Text] [Related]
12. Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: evidence for a sensitive, auto-regulated, receptor-mediated system.
Bartus RT; Elliott P; Hayward N; Dean R; McEwen EL; Fisher SK
Immunopharmacology; 1996 Jun; 33(1-3):270-8. PubMed ID: 8856161
[TBL] [Abstract][Full Text] [Related]
13. The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation.
Emerich DF; Dean RL; Osborn C; Bartus RT
Clin Pharmacokinet; 2001; 40(2):105-23. PubMed ID: 11286321
[TBL] [Abstract][Full Text] [Related]
14. Increased endothelial vesicular transport correlates with increased blood-tumor barrier permeability induced by bradykinin and leukotriene C4.
Hashizume K; Black KL
J Neuropathol Exp Neurol; 2002 Aug; 61(8):725-35. PubMed ID: 12152787
[TBL] [Abstract][Full Text] [Related]
15. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7.
Matsukado K; Inamura T; Nakano S; Fukui M; Bartus RT; Black KL
Neurosurgery; 1996 Jul; 39(1):125-33; discussion 133-4. PubMed ID: 8805148
[TBL] [Abstract][Full Text] [Related]
16. Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy.
Elliott PJ; Hayward NJ; Huff MR; Nagle TL; Black KL; Bartus RT
Exp Neurol; 1996 Oct; 141(2):214-24. PubMed ID: 8812155
[TBL] [Abstract][Full Text] [Related]
17. Low dose of bradykinin selectively increases intracellular calcium in glioma cells.
Wang YB; Peng C; Liu YH
J Neurol Sci; 2007 Jul; 258(1-2):44-51. PubMed ID: 17382350
[TBL] [Abstract][Full Text] [Related]
18. Bradykinin-induced blood-brain tumor barrier permeability increase is mediated by adenosine 5'-triphosphate-sensitive potassium channel.
Zhang H; Gu YT; Xue YX
Brain Res; 2007 May; 1144():33-41. PubMed ID: 17331483
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of low-frequency ultrasound and low-dose bradykinin on increasing permeability of the blood-tumor barrier by opening tight junction.
Zhang Z; Xia C; Xue Y; Liu Y
J Neurosci Res; 2009 Aug; 87(10):2282-9. PubMed ID: 19326437
[TBL] [Abstract][Full Text] [Related]
20. Cereport (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasone.
Dean RL; Emerich DF; Hasler BP; Bartus RT
Neuro Oncol; 1999 Oct; 1(4):268-74. PubMed ID: 11550318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]